Clinical trial
Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant…
NCT00412503 · Gustave Roussy, Cancer Campus, Grand Paris, Other · Completed
Key facts
| NCT number | NCT00412503 |
|---|---|
| Title | Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents |
| Official title | Phase 1 Study of Temozolomide Associated With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents |
| Lead sponsor | Gustave Roussy, Cancer Campus, Grand Paris, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Refractory Tumors, Malignant Tumors |
| Intervention type | Drug |
| Interventions | Topotecan, Temozolomide |
| First posted | Dec 18, 2006 |
| Last update posted | Aug 7, 2009 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: